Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 492-498

  Lee, Meng ^a,b   Saver, Jeffrey L ^a,b   Towfighi, Amytis ^c   Chow, Jessica ^d   Ovbiagele, Bruce ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherogenic dyslipidemia; Cardiovascular disease; Coronary heart disease; Fibrate; Metaanalysis

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COCHRANE LIBRARY; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79960700766     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.020     Document Type: Article

References (32)

1. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:b2376.
2. Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004, 164(13):1427-1436.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
4. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316.
5. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357(13):1301-1310.
6. deGoma E.M., Leeper N.J., Heidenreich P.A. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008, 51(1):49-55.
7. Abourbih S., Filion K.B., Joseph L., et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009, 122(10):e961-968. 962.
8. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393(6687):790-793.
9. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375(9729):1875-1884.
10. Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96(7):2137-2143.
11. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341(6):410-418.
12. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574.
13. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366(9500):1849-1861.
14. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diab Care 2009, 32(3):493-498.
15. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W264.
16. De Caterina R., Scarano M., Marfisi R., et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010, 55(3):198-211.
17. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
19. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions 2008, The Cochrane Collaboration.
20. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
21. Greenland S., Robins J.M. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985, 41(1):55-68.
22. Sterne J.A., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001, 54(10):1046-1055.
23. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102(1):21-27.
24. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study Implications for treatment. Circulation 1992, 85(1):37-45.
25. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317(20):1237-1245.
26. Lee M., Hong K.S., Chang S.C., Saver J.L. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention. A meta-analysis. Stroke 2010, 41(6):1205-1212.
27. Briel M., Ferreira-Gonzalez I., You J.J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
28. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004, 109(1):42-46.
29. Bayturan O., Tuzcu E.M., Lavoie A., et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010, 170(5):478-484.
30. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51(7):724-730.
31. Imke C., Rodriguez B.L., Grove J.S., et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005, 25(8):1718-1722.
32. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308.